Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Activities
Net income (loss)	$ 26,173	$ 16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	5,720	2,961
Gain on sale of asset	(36)	0
Deferred income taxes	11,536	7,140
Amortization of debt origination costs	2,138	995
Stock-based compensation costs	3,047	1,858
Loss on extinguishment of debt	451	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,578	6,956
Inventories	(211)	1,540
Prepaid expenses and other current assets	(1,522)	(2,203)
Accounts payable	783	(3,096)
Accrued liabilities	(7,136)	(3,212)
Net cash provided by (used in) operating activities	43,521	29,671
Investing Activities
Purchases of property and equipment	(780)	(496)
Proceeds from sale of business	344
Acquisition of Care Pharmaceuticals, less cash acquired		(77,991)
Intercompany activity, net		0
Net cash used in investing activities	(436)	(78,487)
Financing Activities
Term loan repayments	(25,000)	0
Borrowings under revolving credit agreement	15,000	65,000
Repayments under revolving credit agreement	(35,000)	(30,000)
Payments of debt origination costs	(4,172)	(74)
Proceeds from exercise of stock options	6,328	1,294
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,600	950
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,171)
Intercompany activity, net	0	0
Net cash (used in) provided by financing activities	(42,887)	36,056
Effects of exchange rate changes on cash and cash equivalents	82	104
Increase (decrease) in cash and cash equivalents	280	(12,656)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	21,598	15,675
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	26,173	16,732
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	989	642
Gain on sale of asset	0
Deferred income taxes	141	(1)
Amortization of debt origination costs	0	0
Stock-based compensation costs	3,047	1,858
Loss on extinguishment of debt	0
Equity in income of subsidiaries	(25,306)	(15,679)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	467
Inventories	0	0
Prepaid expenses and other current assets	(2,152)	947
Accounts payable	861	(936)
Accrued liabilities	(5,668)	(4,800)
Net cash provided by (used in) operating activities	(1,915)	(770)
Investing Activities
Purchases of property and equipment	(648)	(385)
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	(648)	(385)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	6,328	1,294
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,600	950
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,171)
Intercompany activity, net	(4,277)	(13,700)
Net cash (used in) provided by financing activities	2,008	(12,570)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	(555)	(13,725)
Cash and cash equivalents - beginning of period	11,387	24,644
Cash and cash equivalents - end of period	10,832	10,919
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	24,299	17,506
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	146	145
Gain on sale of asset	0
Deferred income taxes	395	892
Amortization of debt origination costs	2,138	995
Stock-based compensation costs	0	0
Loss on extinguishment of debt	451
Equity in income of subsidiaries	(16,955)	(10,898)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	3,171	(130)
Inventories	1,175	3,288
Prepaid expenses and other current assets	(102)	(920)
Accounts payable	(325)	(916)
Accrued liabilities	(2,368)	4,733
Net cash provided by (used in) operating activities	12,025	14,695
Investing Activities
Purchases of property and equipment	0	0
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		(77,991)
Net cash used in investing activities	0	(77,991)
Financing Activities
Term loan repayments	(25,000)
Borrowings under revolving credit agreement	15,000	65,000
Repayments under revolving credit agreement	(35,000)	(30,000)
Payments of debt origination costs	(4,172)	(74)
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	37,147	28,370
Net cash (used in) provided by financing activities	(12,025)	63,296
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	17,927	10,109
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	4,445	2,089
Gain on sale of asset	0
Deferred income taxes	10,866	6,330
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	(1,450)	959
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	735	8,941
Inventories	(1,457)	(2,822)
Prepaid expenses and other current assets	722	(1,706)
Accounts payable	880	(2,918)
Accrued liabilities	975	(5,663)
Net cash provided by (used in) operating activities	33,643	15,319
Investing Activities
Purchases of property and equipment	(27)	(11)
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	(27)	(11)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	(33,616)	(15,308)
Net cash (used in) provided by financing activities	(33,616)	(15,308)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	1,450	(959)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	140	85
Gain on sale of asset	(36)
Deferred income taxes	134	(81)
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(1,328)	(2,322)
Inventories	106	36
Prepaid expenses and other current assets	10	(524)
Accounts payable	(633)	1,674
Accrued liabilities	(75)	2,518
Net cash provided by (used in) operating activities	(232)	427
Investing Activities
Purchases of property and equipment	(105)	(100)
Proceeds from sale of business	344
Acquisition of Care Pharmaceuticals, less cash acquired		(77,991)
Intercompany activity, net		77,991
Net cash used in investing activities	239	(100)
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	746	638
Net cash (used in) provided by financing activities	746	638
Effects of exchange rate changes on cash and cash equivalents	82	104
Increase (decrease) in cash and cash equivalents	835	1,069
Cash and cash equivalents - beginning of period	9,931	3,687
Cash and cash equivalents - end of period	10,766	4,756
Eliminations
Operating Activities
Net income (loss)	(43,676)	(26,656)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	0	0
Gain on sale of asset	0
Deferred income taxes	0	0
Amortization of debt origination costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Equity in income of subsidiaries	43,711	25,618
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0
Inventories	(35)	1,038
Prepaid expenses and other current assets	0	0
Accounts payable	0	0
Accrued liabilities	0	0
Net cash provided by (used in) operating activities	0	0
Investing Activities
Purchases of property and equipment	0	0
Proceeds from sale of business	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash used in investing activities	0	0
Financing Activities
Term loan repayments	0
Borrowings under revolving credit agreement	0	0
Repayments under revolving credit agreement	0	0
Payments of debt origination costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0
Net cash (used in) provided by financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$ 0	$ 0